title: Panitumumab (vectibix).
abstract: Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody.
authors: Department of Radiology, Division of Neuroradiology, University of Michigan Health System, Ann Arbor, 48109, USA. gemmete@med.umich.edu
authors: J J
authors: JJ
authors: Gemmete
authors: S K
authors: SK
authors: Mukherji
references: Am Fam Physician. 2008 Feb 1;77(3):311-9
references: 18297955
references: Drugs. 2010 May 28;70(8):1059-78
references: 20481659
references: Br J Clin Pharmacol. 2009 Oct;68(4):482-3
references: 19843050
references: Clin Colorectal Cancer. 2003 Feb;2(4):246-51
references: 12620146
references: BioDrugs. 2010 Aug 1;24(4):275-8
references: 20623992
references: Ther Clin Risk Manag. 2008 Dec;4(6):1221-7
references: 19337429
references: Core Evid. 2010 Oct 21;5:61-76
references: 21042543
references: Biologics. 2008 Jun;2(2):223-8
references: 19707356
references: Clin Exp Immunol. 2009 Oct;158(1):1-9
references: 19737224